Study Summary
This is a multi-center, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
Want to learn more about this trial?
Request More InfoInterventions
HY004BIOLOGICAL
A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
CyclophosphamideDRUG
Administered intravenously.
Fludarabine PhosphateDRUG
Administered intravenously.
Study Locations
No locations listed.